Mirion Enhances Radiopharmaceutical Production with Cutting-Edge Apex-Guard Software Mirion Technologies (NYSE: MIR), a global leader in radiation safety solutions, has announced the latest release of its Apex-Guard gamma spectroscopy software. Designed to meet the rigorous regulatory standards for commercial radioisotope…
Maternal sepsis is a life-threatening condition that arises from an infection during pregnancy, childbirth, post-abortion, or the postpartum period. It is a significant public health challenge and ranks as the third leading cause of maternal mortality worldwide. In addition to…
WHO Experts Plan Bold Steps to Strengthen Global Immunization The World Health Organization’s Strategic Advisory Group of Experts on Immunization (SAGE) has raised significant concerns about mounting pressures that threaten global vaccination efforts. During its latest meeting from March 10…
Altasciences Wins 2025 CDMO Leadership Award for Small Molecule Dosage Altasciences, a prominent contract development and manufacturing organization (CDMO), has once again been recognized for its excellence in the pharmaceutical industry. The company, which has previously won the CRO Leadership…
Global Cancer Antibody Drug Conjugates Market Report 2024: Industry Growth, Drug Approvals, and Market Expansion The latest report, “Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030,” has been added to ResearchAndMarkets.com’s portfolio.…
Pharma 4.0 Market Report 2025: Projected Growth and Technological Advancements The “Pharma 4.0 – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering, providing an extensive analysis of the evolving Pharma 4.0 market. The global market, valued at $13.7…
Merck’s SC Pembrolizumab Shows Noninferior PK to IV KEYTRUDA in Trial Merck, known as MSD outside of the United States and Canada, has presented the first data from the pivotal 3475A-D77 Phase 3 trial evaluating subcutaneous pembrolizumab in combination with…
Kardigan Acquires Prolaio to Build Innovative Heart Health Platform Kardigan, a heart health company focused on modernizing cardiovascular (CV) drug development, has announced its acquisition of Prolaio, a clinical intelligence company dedicated to advancing cardiology research and care through real-world…
Health Canada Approves 4Moving Biotech’s Phase 2a Trial for Knee Osteoarthritis 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural history of knee osteoarthritis, has received authorization from Health Canada to initiate the…
Savara Secures Up to $200 Million in Non-Dilutive Debt Financing from Hercules Capital Savara Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare respiratory diseases, has announced a significant financial agreement with Hercules Capital, Inc. (NYSE: HTGC).…
Viz.ai AI-Powered Solution Identifies Hypertrophic Cardiomyopathy Earlier, Enhancing Clinical Care Viz.ai, a leading company in AI-powered disease detection and intelligent care coordination, has announced compelling new clinical data demonstrating the effectiveness of its Viz HCM module in detecting hypertrophic cardiomyopathy…
Coya Therapeutics Advances Treg-Derived Exosome Program Coya Therapeutics, Inc. (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function, has provided a comprehensive update on its investigational regulatory T cell-derived exosome…